As of Sep 30, 2024, Regeneron Pharmaceuticals, Inc.'s fair value using the Ben Graham formula is $1,908.3 per share. This is calculated using Ben Graham formula, where EPS is $43.2 and BVPS (Book Value Per Share) is $271.7. The current price of $696.9 suggests Regeneron Pharmaceuticals, Inc. may be overvalued by this conservative metric.
Regeneron Pharmaceuticals, Inc. earnings per share (EPS) for the twelve months ending Sep 30, 2024, was $43.2, a 21.5% growth year-over-year.
Regeneron Pharmaceuticals, Inc.'s margin of safety is positive 173.8%, calculated as (Graham Number - Current Price) / Current Price. A negative margin of safety suggests the stock doesn't provide the level of safety Graham typically sought in his investments.